

CITATION REPORT

List of articles citing

Radiotheranostics in oncology: current challenges and emerging opportunities

DOI: 10.1038/s41571-022-00652-y
Nature Reviews Clinical Oncology, , , .

Source: <https://exaly.com/paper-pdf/148388867/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
32	Preclinical evaluation of 68Ga- and 177Lu-labeled integrin α _v β -targeting radiotheranostic peptides. <i>Jnumed</i> .122.264749		0
31	Antibody-Based Imaging and Therapy for Precision Medicine. 2022 , 19, 3453-3455		0
30	European Association of Nuclear Medicine (EANM) response to the proposed ASTRO β framework for radiopharmaceutical therapy curriculum development for trainees.		1
29	In Vitro and In Vivo Characterization of 89Zirconium-Labeled Lintuzumab Molecule. 2022 , 27, 6589		0
28	Discovery, nuclear properties, synthesis and applications of technetium-101. 2022 , 5,		0
27	Pituitary Adenoma & Nuclear Medicine: recent outcomes and ongoing developments.. 2022 , 104144		0
26	Radiology 2040. 2023 , 306, 69-72		1
25	Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey Holden prostate cancer academy meeting.		0
24	The Logistics of Starting a Radiotheranostics Center in An Academic Institution. 2022 , 45, 491-492		0
23	Philosophy of Cancer Theranostics.		0
22	Astatine-211 based radionuclide therapy: Current clinical trial landscape. 9,		0
21	Electrochemical separation and purification of no-carrier-added 177Lu for radiopharmaceutical preparation: Translation from bench to bed. 2023 , 14, 100444		0
20	A Radioactive and Fluorescent Dual Modality Cysteine Cathepsin-B Activity-Based Probe for Cancer Theranostic.		0
19	Hybrid transcytosis nanopomegranates for sensitizing breast cancer radiotherapy in deep tumor tissue.		0
18	Clinical Translation of Targeted β Therapy: An Evolution or a Revolution?. 265353		0
17	Fractionated Sonodynamic Therapy Using Gold@Poly(ortho-aminophenol) Nanoparticles and Multistep Low-Intensity Ultrasound Irradiation to Treat Melanoma Cancer: In Vitro and In Vivo Studies. 2023 , 49, 1299-1308		0
16	Spatiotemporally confined assembly of radiosensitizers for synergistic radio-chemodynamic therapy on deep tumor of rabbit. 2023 , 50, 101835		0

- 15 Drug-induced Changes on the Biodistribution of Theranostic Radiopharmaceuticals. **2023**, 9, 49-57 ○
- 14 Hallmarks of anticancer and antimicrobial activities of corroles. **2023**, 67, 100931 ○
- 13 Fundamentals of Rhenium-188 Radiopharmaceutical Chemistry. **2023**, 28, 1487 ○
- 12 Nanocarrier-based delivery of arsenic trioxide for hepatocellular carcinoma therapy. **2022**, 17, 2037-2054 ○
- 11 Radiolysis-Associated Decrease in Radiochemical Purity of ¹⁷⁷Lu-Radiopharmaceuticals and Comparison of the Effectiveness of Selected Quenchers against This Process. **2023**, 28, 1884 ○
- 10 Lutetium¹⁷⁷-Labeled DOTA-Ibandronate: A Novel Radiopharmaceutical for Targeted Treatment of Bone Metastases. **2023**, 20, 1788-1795 ○
- 9 [¹¹¹In]In/[¹⁷⁷Lu]Lu-AAZTA5-LM4 SST2R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results. **2023**, 15, 776 ○
- 8 Radiation Oncology and Radiopharmaceuticals: Making Our Own History While Learning From the Past. **2023**, 115, 1044-1046 ○
- 7 An Engineered Probiotic Platform for Cancer Epitope-Independent Targeted Radionuclide Therapy of Solid Tumors. 2202870 ○
- 6 Radiomics and theranostics with molecular and metabolic probes in prostate cancer: toward a personalized approach. **2023**, 23, 243-255 ○
- 5 Cellular proteomic profiling of esophageal epithelial cells cultured under physioxia or normoxia reveals high correlation of radiation response. **2023**, ○
- 4 Hand in Hand Die Zukunft der SPECT- und PET-Bildgebung. **2023**, 62, 52-53 ○
- 3 Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals. **2023**, 15, 1240 ○
- 2 EANM enabling guide: how to improve the accessibility of clinical dosimetry. ○
- 1 ¹⁶¹Tb-PSMA Unleashed: a Promising New Player in the Theranostics of Prostate Cancer. ○